Title: Public health value, cost-eFfectiveness Analysis and modellIng of Reserve antibiotics

Background:

The overarching aim of this project is to develop and pilot a robust and adaptable cost-effectiveness mathematical model to evaluate the public health impact and economic value of the introduction of Reserve antibiotics, such as cefiderocol, in treating severe infections caused by multidrug-resistant Gram-negatives in countries with different epidemiological and economic scenarios. By employing a comprehensive scenario analysis approach, the project will quantify the potential benefits of Reserve antibiotics, including estimating reductions in in-hospital mortality, morbidity (measured in disability-adjusted life-years), and healthcare costs associated with their use across diverse patients’ populations, with particular reference to underserved populations. Furthermore, the project will identify key drivers of value by exploring how factors like antibiotic resistance patterns, treatment costs, healthcare system characteristics, access to old and new antibiotics, and availability of antibiotic, diagnostic, and infection and prevention control stewardship policies influence the overall value proposition of Reserve antibiotics.